Skip to main content

New Oncology, National Cancer Centre Singapore to Collaborate on Cancer Dx

NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration to help the National Cancer Centre Singapore offer personalized cancer treatment using the company's proprietary diagnostic platform, Neo.

Neo enables physicians to optimize treatment for their patients by providing a tumor profile showing all types of therapeutically relevant genetic alterations, including mutations, amplifications, insertions and deletions, as well as novel and known translocations, the firm said in a statement.

Andreas Jenne, CEO of New Oncology, said that the deal is a major milestone in the firm's international business expansion. Financial and other details of the agreement were not disclosed.

New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, is based in Cologne, Germany. Its NeoPlus pan-cancer diagnostic test reliably detects genetic alterations from a single patient sample with short turn-around times.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.